About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- Interstitial Lung Disease / Idiopathic Pulmonary Fibrosis is a high-yield USMLE Step 2 CK respiratory topic requiring diagnosis plus next-best-step management
- Severity assessment comes first: unstable patients need immediate stabilization before definitive diagnostic workup
- Use US guideline pathways, imaging, physiology, microbiology, pathology, or risk scoring depending on the condition
- Management depends on cause, severity, comorbidities, and risk of complications
- Exam stems often hinge on classic clues, contraindications, and when to escalate to imaging, procedure, or ICU care
Overview
Interstitial lung disease refers to a heterogeneous group of disorders involving the alveolar walls, interstitium, small airways, and pulmonary vasculature. Idiopathic pulmonary fibrosis is the prototypical progressive fibrosing ILD and is defined by a usual interstitial pneumonia pattern without identifiable cause.
Epidemiology
IPF typically affects adults older than 60 and is more common in men and former smokers. Risk factors include age, smoking, family history, GERD, metal or wood dust exposure, and certain genetic variants.
Clinical Features
Symptoms
Progressive or acute dyspnea depending on severity and underlying cause
Cough, chest discomfort, fatigue, or exercise limitation
Fever, weight loss, night sweats, or hemoptysis when infection or malignancy is present
Syncope, confusion, severe hypoxemia, or rapidly worsening respiratory distress
Symptoms may be absent when the condition is detected incidentally
Signs
Abnormal breath sounds, crackles, wheeze, dullness, or reduced air entry depending on pathology
Tachypnea, tachycardia, or oxygen desaturation when clinically significant
Cyanosis, hypotension, altered mental status, or respiratory exhaustion
Clubbing, lymphadenopathy, cachexia, or signs of chronic disease when present
Physical examination can be normal in early or mild disease
Investigations
First-line
Focused history and examinationIdentify timing, exposures, smoking, travel, medications, immune status, occupational risks, and red flags
Pulse oximetryRapid assessment of oxygenation and severity
Chest imagingChest X-ray is often initial; CT is used when more anatomic detail, malignancy risk, complications, or alternative diagnosis must be clarified
Second-line
Laboratory testingCBC, CMP, inflammatory markers, cultures, viral testing, autoimmune tests, or disease-specific markers depending on presentation
Pulmonary function testingUseful for chronic dyspnea, obstructive/restrictive patterns, DLCO, and treatment response
Microbiology or pathologySputum studies, cytology, biopsy, or fluid analysis when infection, cancer, or inflammatory disease is suspected
Specialist
Specialist referralPulmonology, infectious disease, oncology, sleep medicine, critical care, or thoracic surgery depending on diagnosis and severity
Advanced testingBronchoscopy, PET-CT, sleep study, HRCT, echocardiography, or interventional radiology procedures when indicated
1
Initial management
- Assess severity, oxygenation, hemodynamics, airway risk, and need for hospital or ICU care
- Treat immediately reversible threats such as hypoxemia, bronchospasm, sepsis, PE, pneumothorax, or respiratory failure
- Use diagnosis-specific guideline therapy rather than empiric escalation without a working differential
2
Definitive treatment
- Treat the underlying cause according to US guideline recommendations
- Use imaging, microbiology, pathology, physiology, and risk stratification to guide therapy
- Escalate to procedural or specialist management when medical therapy is insufficient or diagnosis remains uncertain
3
Follow-up and prevention
- Arrange follow-up imaging or functional testing when recommended
- Address smoking cessation, vaccination, occupational exposure, medication toxicity, and comorbidity optimization
- Educate patients on red flags including worsening dyspnea, hemoptysis, syncope, hypoxemia, or persistent fever
Complications
- Respiratory failure: Severe disease can progress to hypoxemia, hypercapnia, or need for ventilatory support
- Secondary infection: Damaged or obstructed lung is prone to bacterial infection
- Pulmonary hypertension: Chronic hypoxemia or parenchymal disease can increase pulmonary vascular resistance
- Delayed diagnosis: Incidental or nonspecific presentations may hide malignancy, TB, PE, or ILD
- Treatment toxicity: Antimicrobials, corticosteroids, anticoagulants, chemotherapy, or procedures can cause harm
USMLE Step 2 CK Exam Tips
- 1USMLE stems usually reward pattern recognition plus the next best step, not a broad differential alone
- 2Always separate unstable patients from stable patients before choosing imaging or outpatient follow-up
- 3Hypoxemia, altered mental status, hypotension, or rapidly worsening dyspnea usually changes the answer to urgent stabilization
- 4CT is favored over MRI for most acute pulmonary diagnostic pathways
- 5Smoking history, hemoptysis, weight loss, and recurrent focal pneumonia are malignancy clues
- 6Use disease-specific guideline thresholds rather than treating every abnormal image or test result the same way
practicetest your knowledge on interstitial lung disease / idiopathic pulmonary fibrosisApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — respiratory and beyond.
open q-bank